Results From Trial of Simvastatin for SPMS Expected in 2025

Results From Trial of Simvastatin for SPMS Expected in 2025

314893

Results From Trial of Simvastatin for SPMS Expected in 2025

MS-STAT2, a clinical trial testing whether the cholesterol-lowering medication simvastatin might slow disability progression in secondary progressive multiple sclerosis (SPMS), has finished enrollment. A total of 964 people are now in the trial (NCT03387670), making it the largest progressive MS trial not run by a commercial company (MS-STAT2 is sponsored by University College London). Results from the trial are expected in 2025. “We are delighted to have completed recruitment for MS-STAT2, a landmark trial for…

You must be logged in to read/download the full post.